1-methyl-3-(2-(naphthalen-2-yl)-2-oxoethyl)-1H-imidazol-3-ium bromide | 121704-58-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-methyl-3-(2-(naphthalen-2-yl)-2-oxoethyl)-1H-imidazol-3-ium bromide
• 英文别名: 1-methyl-3-(2-naphth-2-yl-2-oxoethyl)imidazolium bromide；2-(3-Methylimidazol-3-ium-1-yl)-1-naphthalen-2-ylethanone;bromide
• CAS: 121704-58-3
• 化学式: Br*C₁₆H₁₅N₂O
• 分子量: 331.212
• InChiKey: DTNSZAUTDFMKGD-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -0.65
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  25.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-甲基咪唑 、 2-溴代-2-乙酰基萘 以 乙醇 为溶剂， 以73%的产率得到1-methyl-3-(2-(naphthalen-2-yl)-2-oxoethyl)-1H-imidazol-3-ium bromide
  参考文献：
  名称：

  离子液体可溶性光敏剂

  摘要：

  报道了设计成优先溶于室温离子液体的三线态光敏剂的制备和研究。通过将1-甲基咪唑共价连接到芳基酮上制备的光敏剂可溶于离子液体，并在用有机溶剂萃取溶液时保留在离子液体层中。在离子液体溶液中有效地进行了反式-β-紫罗兰醇向顺式-β-紫罗兰酚的光敏异构化，提取了产品紫罗兰醇，并将敏化剂/离子液体混合物重新用于其他光敏反应中。讨论了敏化剂在敏化其他反应中的范围和用途。

  DOI：

  10.1016/j.tet.2005.05.072
• 作为试剂：
  描述：

  diethyl 4-(4-methoxyphenyl)-1,4-dihydropyridine-3,5-dicarboxylate 在 1-methyl-3-(2-(naphthalen-2-yl)-2-oxoethyl)-1H-imidazol-3-ium bromide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.0h， 以49%的产率得到tetraethyl 6,12-bis(4-methoxyphenyl)-3,9-diazahexacyclo[6.4.0.0^2,7.0^4,11.0^5,10]dodecane-1,5,7,11-tetracarboxylate
  参考文献：
  名称：

  Triplet phenacylimidazoliums-catalyzed photocycloaddition of 1,4-dihydropyridines: An experimental and theoretical study

  摘要：

  The photocycloadditions of 1,4-dihydropyridines (DHPs) were achieved by using phenacylimidazoliums (Plms) as photosensitizers. Irradiation of DHPs 3a-g in the presence of Plms 1a-e and 2 performed an efficient formation of 3,9-diazatetraasteranes in shorter times under a lower power lamp. The mechanism of photocycloaddition catalyzed by Plm was studied by laser flash photolysis and theoretical OFT computation. These time-resolved results showed that the triplet excited states of Plms were generated with high efficiency and detected by their characteristic ultraviolet absorptions, which were quenched by DHP at almost diffusion controlled rate. Theoretical studies suggest that Plm is involved in the photocycloaddition process through the (3)(DHP center dot center dot center dot Plm)* triplet complexes and assists the stabilization of intermediates. All subsequent steps are predicted to be favorable and exothermic, leading to the cage dimers. (C) 2012 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jphotochem.2012.05.013

文献信息

• 18F-LABELED PRECURSOR OF PET RADIOACTIVE MEDICAL SUPPLIES, AND PREPARATION METHOD THEREOF
  申请人：Chi Dae-Yoon

  公开号：US20140194620A1

  公开（公告）日：2014-07-10

  The present invention relates to a precursor of positron emission tomography (PET) radioactive medical supplies, a preparation method thereof, and an application thereof, and more specifically, to a precursor having a tetravalent organic salt leaving group, a preparation method, and a method for preparing desired PET radioactive medical supplies in a high radiochemical yield within a short preparation time by introducing 18 F using the same through a single step. The precursor having a tetravalent organic salt leaving group of the present invention can simplify the known complex multistep preparation of radioactive medical supplies into a single step, can save production costs because an excessive amount of a phase transfer catalyst is not required, facilitates separation of a compound after reaction, and enables rapid reaction velocity. The features are appropriate for the mass production of PET radioactive medical supplies by an automated synthesis system.

  本发明涉及正电子发射断层扫描（PET）放射性医疗用品的前体、其制备方法及应用，更具体地，涉及一种具有四价有机盐离基的前体、其制备方法，以及通过引入 18 F并通过单步骤使用相同物质在短时间内高放射化学产率制备所需PET放射性医疗用品的方法。本发明的具有四价有机盐离基的前体可以将已知的复杂多步制备放射性医疗用品简化为单步骤，因为不需要过量的相转移催化剂，可以节省生产成本，促进反应后化合物的分离，并实现快速反应速度。这些特点适用于通过自动合成系统大规模生产PET放射性医疗用品。
• Method for treating fibrotic diseases or other indications IC
  申请人：Alteon, Inc.

  公开号：US20020068729A1

  公开（公告）日：2002-06-06

  Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: 1

  提供了一种处理、改善或预防动物包括人类发明的指示的方法，包括给予公式I的化合物的有效量：1
• Method for treating fibrotic diseases or other indications with imidazolium agents
  申请人：Alteon, Inc.

  公开号：US20030176426A1

  公开（公告）日：2003-09-18

  Provided is a method of treating or ameliorating an indication of the invention in an animal, including a human, by administering an effective amount of a compound of the formula I: 1 wherein R 1 , R 2 , M, X and Z are as described supra. Also provided are certain imidazolium compounds and pharmaceutical compositions containing the imidazolium compounds.

  提供了一种治疗或改善动物（包括人类）发明的征兆的方法，通过给予公式I的有效量的化合物： 1 其中R 1 ，R 2 ，M，X和Z如上所述。还提供了一些咪唑啉化合物和包含咪唑啉化合物的药物组合物。
• Ionic liquid soluble photosensitizers
  作者：Sarah C. Hubbard、Paul B. Jones

  DOI：10.1016/j.tet.2005.05.072

  日期：2005.8

  preparation and investigation of triplet photosensitizers designed to be preferentially soluble in room-temperature ionic liquids are reported. Photosensitizers prepared by covalent attachment of 1-methylimidazole to aryl ketones are soluble in ionic liquids and remain in the ionic liquid layer when the solution is extracted with an organic solvent. The photosensitized isomerization of trans-β-ionol to cis-β-ionol

  报道了设计成优先溶于室温离子液体的三线态光敏剂的制备和研究。通过将1-甲基咪唑共价连接到芳基酮上制备的光敏剂可溶于离子液体，并在用有机溶剂萃取溶液时保留在离子液体层中。在离子液体溶液中有效地进行了反式-β-紫罗兰醇向顺式-β-紫罗兰酚的光敏异构化，提取了产品紫罗兰醇，并将敏化剂/离子液体混合物重新用于其他光敏反应中。讨论了敏化剂在敏化其他反应中的范围和用途。
• Method for treating fibrotic diseases or other indications ID
  申请人：——

  公开号：US20020177586A1

  公开（公告）日：2002-11-28

  Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: 1

  提供了一种在动物中（包括人类）治疗、改善或预防本发明指示的方法，其中包括给予化合物I的有效量：1。